Real-world Data Continues Showing Benefits of Takeda’s Entyvio for IBD Patients

Real-world Data Continues Showing Benefits of Takeda’s Entyvio for IBD Patients
Real-world data demonstrates the safety, tolerability, and efficacy of Entyvio (vedolizumab) in treating ulcerative colitis (UC) and Crohn's disease, confirming previous data collected in clinical trials. These findings were the focus of two poster presentations during the recent 25th United European Gastroenterology (UEG) Week in Barcelona, Spain. Entyvio, developed by Japan's Takeda Pharmaceutical, reduces inflammation in the intestinal mucosa by blocking immune cells from entering inflamed tissue. At least 60 countries have approved it to treat adults with moderate to severe UC and Crohn'
Subscribe or to access all post and page content.

One comment

  1. Lynn Santaniello says:

    I had constant infections in, & around my med port while on Entyvio !! It did nothing for my Crohn’s in the year and a half of being on it. I had to stop it due to the infections, & my port stopped getting infections.

Leave a Comment

Your email address will not be published. Required fields are marked *